INDEMNIFICATION AGREEMENTIndemnification Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”), dated as of [DATE], is by and between Lantern Pharma Inc., a Delaware corporation (the “Company”) and [NAME OF DIRECTOR/OFFICER] (the “Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Texas
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as March 17, 2017, by and among Lantern Pharma Inc., a Texas corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.8 hereof.
ADDENDUM TO TECHNOLOGY LICENSE AGREEMENT by and between AF CHEMICALS LLC and LANTERN PHARMA, INC.Technology License Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This Addendum is attached to and forms part of the Technology License Agreement by and between Lantern Pharmaceuticals Inc., a Texas corporation (hereinafter referred to as “LANTERN”) having principal offices at 4287 Beltline Rd., Suite #270, Addison, TX 75001 and AF Chemicals, LLC, a Californian Limited Liability Company having principal offices at 5545 Coral Reef, La Jolla, CA 92037 (hereinafter referred to as “AFC”) as of February 8, 2016 (the “EFFECTIVE DATE”) (hereinafter the “LANTERN AFC ADDENDUM”). LANTERN and AFC are sometimes each individually referred to hereinafter as a “Party” and collectively referred to hereinafter as the “Parties”. To the extent that any of the terms or conditions contained in this LANTERN AFC ADDENDUM may contradict or conflict with any of the terms or conditions of the Technology License Agreement dated January 15, 2015, it is expressly understood and agreed that the terms of this LANTERN AFC ADDENDUM shall take precedence and supersede the Technology
ADDENDUM TO DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APSDrug License and Development Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This Addendum is attached to and forms part of the DRUG LICENSE AND DEVELOPMENT AGREEMENT dated May 23, 2015 (hereinafter the “Addendum”), between Oncology Venture APS (Company Registration no. 34 62 35 62), a Danish corporation having its principal offices at Venlighedesvej 1, 2970 Hørsholm, Denmark (hereinafter “OV”), and Lantern Pharma, Inc, (Company Registration no. ______________________________ ) a Texas corporation having its principal place of business at 211 N Ervay Street, Suite 404, Dallas, TX 75201 U.S.A. (hereinafter “LP”) as of February 8, 2016 (the “EFFECTIVE DATE”) (hereinafter the “Addendum”). LP and OV are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. To the extent that any of the terms or conditions contained in this Addendum may contradict or conflict with any of the terms or conditions of the Drug License and Development Agreement dated May 23, 2015, it is expressly understood and agreed that the terms of this Addendum sh
AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Texas
THIS AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”), is made and entered into as of March 17, 2017, by and among Lantern Pharma Inc., a Texas corporation (the “Company”), the holders of the Company’s Series A Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”) listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Sections 7.1(a) or 7.2 below, the “Investors”), and those certain stockholders of the Company listed on Schedule B (together with any subsequent stockholders, or any transferees, who become parties hereto as “Key Holders” pursuant to Sections 7.1(b) or 7.2 below, the “Key Holders,” and together collectively with the Investors, the “Stockholders”).
AMENDMENT NO. 2 TO DRUG LICENSE AND DEVELOPMENT AGREEMENTDrug License and Development Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This Amendment Number Two (“Amendment No. 2”), to the existing and in-force Drug License And Development Agreement (the “Agreement”) between the parties hereto (effective as of May 23, 2015), is entered into by and between Oncology Venture A/S, a Danish corporation having its principal offices at Venlighedesvej 1, 2970 Hørsholm, Denmark (“OV”), and Lantern Pharma, Inc., a Texas corporation having its principal place of business at 211 N Ervay Street, Suite 404, Dallas, TX 75201 U.S.A. (“LP”) as of February 11, 2016 (the “Effective Date”). LP and OV are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ASSIGNMENT AGREEMENTAssignment Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Texas
THIS ASSIGNMENT AGREEMENT (the “Agreement”) is made and entered into, as of the Effective Date, by and between Lantern Pharma, Inc. (hereinafter referred to as “Lantern”) and BioNumerik Pharmaceuticals, Inc. (hereinafter referred to as “BioNumerik”), with regard to the assignment of rights to the Compound (defined below) in the Field (defined below) in the Territory (defined below).
DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APSDrug License and Development Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • New York
This Drug License And Development Agreement (the “Agreement”) is entered into and effective as of May 23, 2015 (the “Effective Date”) by and between Oncology Venture Aps, (Company Registration no. 34 62 35 62) a Danish corporation having its principal offices at Venlighedesvej 1, 2970 Hørsholm, Denmark (“OV”), and Lantern Pharma, Inc, (Company Registration no. __________________________) a Texas corporation
AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Texas
THIS AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of March 17, 2017, by and among Lantern Pharma Inc., a Texas corporation (the “Company”), the Investors listed on Schedule A and the Key Holders listed on Schedule B.
